NasdaqCM - Nasdaq Real Time Price USD

INVO Fertility, Inc. (NAYA)

1.8900

-0.3700

(-16.37%)

At close: April 15 at 4:00:01 PM EDT

NAYA Biosciences Announces Strategic Decision to Separate Fertility and Oncology Businesses into Distinct Operations – Company Renamed “INVO Fertility, Inc.”

Public company to operate under new name and concentrate on building, acquiring and operating fertility clinics and the distribution of FDA-cleared INVOcell device Private company to operate as NAYA Therapeutics and focus on clinical development of bifunctional antibodies SARASOTA, Fla., April 14, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc., formerly known as NAYA Biosciences, Inc. (the “Company”) (Nasdaq: NAYA), a healthcare services fertility company focused on expanding access to advanced t

GlobeNewswire yesterday

NAYA
-16.37%
NAYA Announces a 1:12 Reverse Stock Split Effective Pre-Market Opening on March 18, 2025

SARASOTA, Fla. and MIAMI, March 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences, Inc. (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, and a leading provider of in vitro fertilization (IVF) and in vivo Intravaginal Culture (“IVC”) fertility treatments, announced today that it will effect a 1-for-12 reverse split of its issued and outstanding and authorized common stock effective

GlobeNewswire last month

NAYA
-16.37%
NAYA Biosciences Supports Recent Executive Order Aimed at Improving Access to Fertility Treatment

NAYA Sees Potential Positive Impact to Its Existing Fertility Operations and FDA-Cleared INVOcell TechnologySARASOTA, Fla. and MIAMI, Feb. 25, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences, Inc. (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, and a leading provider of in vitro fertilization (IVF) and in vivo Intravaginal Culture (“IVC”) fertility treatments, proudly supports the

GlobeNewswire last month

NAYA
-16.37%
NAYA Biosciences Announces Nomination of New Board Members

New board reflects company’s added focus on oncology & autoimmune diseases SARASOTA, Fla. and MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, today announced that its board of directors has nominated five new candidates with extensive experience in in the biotechnology industry to be approved at the company shareholder

GlobeNewswire last month

NAYA
-16.37%
KYMR

BDTX
NAYA Biosciences Announces Pricing of $9.5 Million Public Offering

SARASOTA, Fla. and MIAMI, Jan. 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, today announced the pricing of a public offering of an aggregate of 13,615,171 units at a public offering price of $0.70 per unit. Each unit consists of one share of common stock (or pre-funded warrant in lieu thereof) and one warrant to purchase one sh

GlobeNewswire 2 months ago

NAYA
-16.37%
NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody

• PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications • NAYA aiming to initiate clinical trials in early 2026 SARASOTA, Fla. and MIAMI, Jan. 06, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, today announced that it is expanding its bifunctional antibody pipeline

GlobeNewswire 3 months ago

NAYA
-16.37%
NAYA Biosciences to Present Translational Insights to Support Phase I/IIa Clinical Trials for its GPC3-Targeting NK Engager Bispecific Antibody at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Abstracts demonstrate reversal of resistance to PD1 checkpoint blockade and predictive AI model of HCC survival rateSARASOTA, Fla. and MIAMI, Oct. 31, 2024 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and fertility, today announced that it is presenting novel insights into the mode of action of its GPC3-targeting NK engager bispecific antibody NY-303 to su

GlobeNewswire 5 months ago

NAYA
-16.37%
NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma

SARASOTA, Fla. and MIAMI, Oct. 24, 2024 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and fertility, today announced an update regarding its clinic trial plans. The Company received regulatory approval from the Israeli Ministry of Health in July 2024 and subsequent institutional review board clearance to initiate patient enrollment in up to 7 academic cente

GlobeNewswire 5 months ago

NAYA
-16.37%

Performance Overview

Return	NAYA	S&P 500 (^GSPC)
YTD	-80.56%	-8.25%
1-Year	-79.47%	+6.61%
3-Year	-99.58%	+22.86%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

INVO Fertility, Inc. (NAYA)

NAYA Biosciences Announces Strategic Decision to Separate Fertility and Oncology Businesses into Distinct Operations – Company Renamed “INVO Fertility, Inc.”

NAYA Announces a 1:12 Reverse Stock Split Effective Pre-Market Opening on March 18, 2025

NAYA Biosciences Supports Recent Executive Order Aimed at Improving Access to Fertility Treatment

NAYA Biosciences Announces Nomination of New Board Members

NAYA Biosciences Announces Pricing of $9.5 Million Public Offering

NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody

NAYA Biosciences to Present Translational Insights to Support Phase I/IIa Clinical Trials for its GPC3-Targeting NK Engager Bispecific Antibody at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma

Performance Overview